A prospective single-arm phase II clinical study of low-dose radiotherapy combined with tislelizumab and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma (stage II-IIIB)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500105610

Enrollment

Unknown

Registered

2025-07-07

Start date

2025-08-01

Completion date

Unknown

Last updated

2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma (ESCC)

Interventions

Treatment group:Neoadjuvant therapy before surgery, surgical treatment, and adjuvant therapy after surgery

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The primary tumor is resectable (T2-4aN0-1M0); 2. No prior anti-tumor treatment (chemotherapy, radiotherapy, immunotherapy) has been received; 3. Normal function of vital organs (bone marrow, liver, and kidney function); 4. Informed consent form has been signed;

Exclusion criteria

Exclusion criteria: 1. Tumor invasion of major blood vessels or trachea (T4b); 2. Presence of other malignancies or severe cardiopulmonary diseases (e.g., NYHA Class III heart failure); 3. Immune deficiency (e.g., HIV infection, long-term use of immunosuppressive agents); 4. Pregnant or breastfeeding women;

Design outcomes

Primary

Measure	Time frame
pathologic complete response;Main pathological remission;	—

Secondary

Measure	Time frame
objective response rate;progression-free survival;Overall survival;safety;	—

Countries

China

Contacts

Public ContactQifei Wu

The First Affiliated Hospital of Xi'an Jiaotong University

wuqifei@xjtufh.edu.cn+86 29 85323215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026